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Preserve the Brain
Primary Goal in the Therapy of
Atrial Fibrillation*
Eric N. Prystowsky, MD, Benzy J. Padanilam, MD
Indianapolis, Indiana
Treatment of atrial ﬁbrillation (AF) involves 3 major strat-
egies: prevention of stroke, maintenance of sinus rhythm,
and rate control (1). Stroke is the most dreaded complication
of AF, and its prevention is key. Anticoagulation with
warfarin and the newer agents dabigatran, rivaroxaban, and
apixaban is highly effective in preventing strokes in patients
with AF (1–4). However, deﬁning the appropriate patient
for anticoagulant therapy is not an exact science, and the
stroke risk schema CHADS2 (Congestive heart failure,
Hypertension, Age 75 years, Diabetes mellitus, previous
Stroke/transient ischemic attack) and CHA2DS2-VASc
(Vascular disease, Age 65–74 years, [female] Sex category)
have only modest predictive ability (5). Unfortunately, stroke
See pages 525 and 531
is not the only neurological consequence of AF. Cognitive
impairment and silent cerebral infarcts (SCIs) without
clinical strokes have been reported in patients with AF.
Kilander et al. (6) showed that AF was associated with
low cognitive function in elderly men independent of
stroke. Further, memory impairment and hippocampal
atrophy were identiﬁed in a group of stroke-free patients
with AF and a mean age of 60 years (7). Bunch et al. (8,9)
demonstrated that AF was independently associated with
Alzheimer’s disease and other forms of dementia, with
the greatest risk in those 70 years of age. There is also
a greater rate of decline in Alzheimer’s disease with AF (10).
Population studies appear to show that diabetes mellitus,
a disease associated with a high risk of stroke, is an inde-
pendent risk factor for AF, adding another variable to affect
neurological function (11,12). Although patients undergoing
ablation for AF have been reported to have lower risks
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(13) as well as silent cerebral embolic lesions detected
by magnetic resonance imaging (MRI) (14–16). Lastly, AF
is often asymptomatic but may have a signiﬁcant stroke
risk (1,17–20).
Two studies in this issue of the Journal (21,22) provide
signiﬁcant new insights on the effect of AF on more subtle
neurological problems. Marfella et al. (21) evaluated the
prevalence of subclinical AF and its relationship to SCI and
stroke in otherwise healthy diabetic patients younger than
60 years of age. Asymptomatic AF episodes were discovered
using intermittent 48-h Holter monitors quarterly in the
ﬁrst year and annually for another 3 years of follow-up. MRI
of the brain was performed at baseline to evaluate for SCI. In
total, 465 of 1,992 patients met the study criteria. Patients
who developed clinical AF during follow-up were excluded;
thus, any AF in the study group was subclinical and iden-
tiﬁed only as a result of the Holter monitoring. After an
average follow-up of 37 months, 176 of 465 diabetic patients
had silent episodes of AF (SAFE group). The prevalences of
SCI (61% vs. 29%; p < 0.01) and stroke (17.3% vs. 5.9%;
p < 0.01) were signiﬁcantly higher in this group compared
with diabetic patients without silent episodes of AF (non-
SAFE group, n ¼ 288). The mean duration of AF was
21  15 h, and the absolute burden of AF correlated to the
number and size of SCIs. The study also compared these
diabetic patients with 240 nondiabetic case controls. The
prevalences of silent AF and SCIs were very low, at 1.5%
and 0.5%, respectively, in the control group. By design,
therapeutic options were not evaluated. It is unclear from
this report why a much lower percent of patients in the
entire diabetic cohort (212 of 1,992; 11%) had silent AF
compared with those who met the study criteria (176 of 465;
38%). A ﬂowchart of patient selection would have helped
with clarity. Despite these methodological drawbacks, the
study ﬁndings are rather startling. First, brief asymptomatic
episodes of AF occur frequently in diabetic patients. The
11% incidence of subclinical AF in the study, while already
high, is almost certainly an underestimation due to the
intermittent nature of the monitoring for arrhythmia.
Second, subclinical AF events are associated with a high
prevalence of SCI and subsequent development of stroke.
Although the high prevalence of SCIs in the SAFE group
may be readily attributed to AF, the non-SAFE group also
had a relatively high prevalence of SCIs. Thus, many of the
SCIs could be unrelated to AF events in either population or
the study failed to detect AF events in the non-SAFE group.
In the second report, Medi et al. (22) evaluated whether
post-procedural cognitive dysfunction (POCD) occurs after
radiofrequency catheter ablation (RFA) of AF. Patients
undergoing RFA for paroxysmal AF (n ¼ 60) and persistent
AF (n ¼ 30) were compared with 30 patients undergoing
RFA for supraventricular tachycardia (SVT), 7 of whom
underwent a left atrial procedure, and 30 control patients with
AF awaiting RFA. A trans-septal approach was used to ac-
cess the left atrium. In patients undergoing anticoagulation
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541therapy before ablation for AF, warfarin was stopped 5 days
before the procedure and full-dose enoxaparin was given.
After ablation, enoxaparin was continued until warfarin was
therapeutic. All ablations were performed with the patient
under general anesthesia, and there was no difference in the
depth of anesthesia among the patient groups. Importantly,
there was no evidence of clinical stroke after any of the
ablations, although MRI studies to evaluate for SCI were not
performed. Neuropsychological testing to determine POCD
included 8 tests from the Canadian Study of Health and
Aging and was conducted by a trained interviewer. The
number of correct answers or the time taken to complete the
test composed the results. The test was given 3 times: at
baseline within 7 days before the procedure, 24 to 48 h after
the procedure, and 3 months after the procedure. Analysis of
the test scores used the reliable change index, and POCD was
deﬁned as a score of less than1.96 on 2 tests or more and/or
a combined z score of less than 1.96.
Patients with left-sided SVT had shorter left atrial access
time and RFA time than did patients with AF. POCD was
assessed 36  10 h after RFA and at 39  18 h in the AF
control group. The incidence of POCD was 28%, 27%, and
13%, respectively, in the paroxysmal AF, persistent AF, and
SVT groups. No deterioration was noted in any of the
control patients. At the 3-month post-operative assessment,
POCD was present in 13%, 20%, and 3% of patients with
paroxysmal AF, persistent AF, and SVT, respectively. The
incidences of POCD did not differ between the paroxysmal
and persistent AF groups.
It has been well recognized for many years that cognitive
decline can occur after coronary artery bypass surgery (23).
However, data showing cognitive impairment after ablation
for AF are disturbing and require further investigation
(22,24). It will be important for future studies of POCD to
incorporate MRI to determine whether SCI is associated
with cognitive impairment, although it was not in one small
study (24). It is unclear if performing ablations for AF with
therapeutic warfarin anticoagulation would reduce the inci-
dence of POCD. Different forms of ablation and anti-
coagulation strategies need to be evaluated to determine
their comparative effect on POCD.
These 2 studies raise several important new questions. If
the neurological sequelae of AF are not limited to stroke,
have we omitted an important endpoint in the current state
of AF management? Studies of anticoagulation in AF have
only addressed endpoints of strokes and systemic emboli-
zation and not SCI or cognitive deterioration. In fact, it
is possible that anticoagulation itself may lead to cerebral
microhemorrhages and neurological dysfunction. Future
studies of AF should evaluate SCI and cognitive dysfunction
as end points.
How can we reduce the harmful neurological effects of
AF in our patients? In our opinion, it will take a multi-
pronged approach that includes re-evaluation of the safety
of the rate control approach to AF. The apparent safety of
this treatment strategy is based mainly on the results ofthe AFFIRM and RACE trials (25,26), which compared
pharmacological rate control with rhythm control. The age
of the patient populations studied was narrow (mean of 69.7
and 68 years, respectively), and the follow-up time was only
a mean of 3.5 and 2.3 years, respectively. More recent data
from a population-based database showed that patients
treated with rhythm control drugs had reduced mortality
when the follow-up was extended beyond 4 years (27).
Using this same database, Tsadok et al. (28) concluded that
patients treated with rhythm control drugs, especially those
with a CHADS2 risk of 1, had lower rates of stroke/
transient ischemic attack with a similar number of patients
treated with anticoagulation in the rate and rhythm control
groups. Thus, we believe that the long-term safety of
persistent AF has not been deﬁnitively established, especially
in younger patients. The lack of outcomes data on neuro-
cognitive function and SCIs should be considered when
a rate control strategy is used in patients with AF.
We also need to identify patients with silent AF and a
signiﬁcant stroke risk, for example, the elderly or those with
hypertension or diabetes, with the hope that appropriate
anticoagulation will reduce the incidences of stroke and TIA.
At present, monitoring using pacemakers or deﬁbrillators
(17,18), Holter monitors, or handheld recorders (19,21,29)
may provide such information in some patients. Hopefully,
consumer-friendly and cost-effective long-term electrocar-
diographic monitors will be readily available in the primary
care setting to monitor speciﬁc patient populations for sub-
clinical AF. At present, it is not known whether prescribing
anticoagulants to patients with silent AF at high risk for
stroke will reduce that risk, and randomized trials are needed
to answer this important question. Detection of AF in such
patients will allow the physician to discuss the relative merits
of such therapy for each patient. Although ablation therapy
appears to reduce some of the complications of AF (9), it is
also associated with stroke, SCI, and POCD, and more
research is needed to determine methods to reduce these risks.
In summary, we must do more to identify asymptomatic
AF and evaluate new strategies to fulﬁll the ﬁrst command-
ment of therapy for patients with AF: preserve the brain.Reprint requests and correspondence: Dr. Eric N. Prystowsky,
St. Vincent Medical Group, 8333 Naab Road, Suite 400, Indianapolis,
Indiana 46260. E-mail: enprysto@stvincent.org.REFERENCES
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